Most AI-driven biopharma companies parse available data to find drug molecules that target single proteins believed to underlie a disease. This yields a lot of leads, but few pan out. Recursion ...

Recursion, a biotech company making new drugs using AI technology, just closed a $121 million Series C round with investors like the venture-capital firm Menlo Ventures.

Precision-designed using Recursion’s generative AI and active learning platform to optimize for non-covalent binding and ADME/PK, potentially delivering a broader therapeutic window, reduced off ...

Salt Lake City-based biotech Recursion Pharmaceuticals, which is part of the group of companies looking to use AI technology to accelerate drug development, has raised a $121 million Series C ...